Congress has directed the health regulator to allow personal drug importation when the practice poses no unreasonable risk to the individual, a stance codified in a 2003 amendment to the Federal Food, Drug, and Cosmetic Act.
The amendment was part of the Medicare Prescription Drug, Improvement, and Modernization Act, signaling congressional intent to ease cost barriers for patients.
Congressional mandate on personal drug importation
The provision declares that the Secretary of Health and Human Services should exercise enforcement discretion to permit otherwise non-compliant drug importation when it is “clearly for personal use” and does not “appear to present an unreasonable risk to the individual.”
Its language uses the term “should,” which conveys a strong advisory purpose rather than a discretionary option left to agency interpretation.
That provision, often called the discretion clause, sits alongside two separate waiver provisions that permit broader import programs, including a Canada-specific pathway.
The Senate, following amendments proposed by Senator Byron Dorgan, divided personal importation into three provisions (j)(1), (j)(2), and (j)(3).
FDA’s internal policy versus statutory directive
The agency has long operated under a Personal Importation Policy (PIP), an internal guideline that predates the 2003 amendment. The policy focuses on “unapproved” medicines rather than lower-cost equivalents of drugs already sold in U.S. pharmacies.
Because the PIP predates the statutory amendment, it remains an internal policy rather than a statutory directive.
When the regulator encounters a shipment that violates the act, the PIP usually leads to refusal and destruction of the product, even if the medication is a cheaper version of a brand-name drug.
Data from 2022 show the agency examined nearly 53,000 imported consignments; only 33 contained opioids, and none involved fentanyl. The vast majority were non-controlled prescriptions for chronic conditions.
Read Also: Probation Can Be Revoked Without Explanation
These figures illustrate that opioid interceptions represent a minute fraction of overall imports.
More recent figures indicate that roughly 72,000 drug products were denied entry over a twelve-month period, with most being incinerated.
The amendment was part of a broader effort to modernize drug policy, aiming to balance safety with access.
By isolating the discretion clause from waiver mechanisms, Congress assigned each paragraph a distinct function, giving agencies a clear, independent basis for permitting imports that meet the risk threshold.
Judicial interpretation of the enforcement clause
Legal scholars have debated whether the discretion clause carries independent legal weight. If it does, the regulator’s practice must align with Congress’s intent.
The statute’s architecture separates wholesale import programs (subsections (b)-(h)) from the personal-use provisions (subsection (j)). The latter is further divided into three parts: the discretion clause, a general waiver authority, and a Canada-only waiver.
Legislative history shows the Senate, guided by Senator Byron Dorgan, split the personal-use rules into those three distinct pieces, reinforcing the idea that each serves a different function.
In Vermont v. Leavitt (2005), a trial court mistakenly applied a certification requirement meant for wholesale imports to the personal-use rules. The Secretary’s 2020 certification, however, addressed only the wholesale sections, leaving the personal-use clause untouched.
From a broader perspective, the tension highlights how statutory language can shape regulatory behavior. When lawmakers explicitly state that the agency “should” permit certain imports, the regulator’s internal policies should reflect that direction, or risk being viewed as overstepping its statutory bounds.
Policy implications and next steps
Consumer groups estimate that about 2.3 million Americans rely on cross-border purchases each year to save on prescription costs. The current practice of destroying these
